{"id":237870,"date":"2026-09-09T13:21:50","date_gmt":"2026-09-09T07:51:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237870"},"modified":"2026-09-09T13:21:50","modified_gmt":"2026-09-09T07:51:50","slug":"is-bliss-gvs-pharma-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-bliss-gvs-pharma-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Bliss GVS Pharma a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Bliss GVS Pharma share price around Rs 701. 3.5% below 52-week high of Rs 726. Q1 FY27 revenue Rs 295 crore, up 21.5% YoY. PAT Rs 51 crore, up 15.8%. PE 54x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Bliss GVS Pharma’s Q1 FY27 results were strong, with revenue at Rs 295 crore and PAT climbing 16% to Rs 51 crore. The stock trades at a PE of 54x against an industry average near 38x, so some of this good news is already priced in. The Bliss GVS Pharma share price near Rs 701 reflects that optimism, so investors weighing whether Bliss GVS Pharma is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/p><\/div>\n

The Bliss GVS Pharma share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bliss GVS Pharma is a manufacturer of pharmaceutical formulations, particularly suppositories and specialty dosage forms, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 295 crore, up 21.5% year on year, while profit after tax came in at Rs 51 crore, up 15.8% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bliss GVS Pharma share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Bliss GVS Pharma share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n